Clinical trials: Cancer of the Prostate
Metastatic, Androgen Independent Prostate Cancer, Prostate Cancer
The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer
The purpose of this study is to evaluate the safety and optimal dose of RAD001 and docetaxel plus prednisone in men with hormone refractory, metastatic prostate cancer (Phase I).
- Trial name
- NCT00459186
- Testing
- RAD001, Docetaxel, Prednisone
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
The purpose of this study is to evaluate the immune response induced by sipuleucel-T (Provenge®).
- Trial name
- PRIME (NCT01727154)
- Testing
- Sipuleucel-T
- Where
- 39 sites in United States
- Volunteers
- 139 people
- Sponsor
- Dendreon
Prostate Cancer
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
The purpose of this study is to determine the clinical benefits of using a rapidly cycling, non-cross reactive regimen of FDA-approved prostate cancer therapeutic agents in the management of castration resistant prostate cancer.
- Trial name
- NCT02903160
- Testing
- Abiraterone acetate, Prednisone, Radium-223 dichloride
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Prostate Cancer
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
The purpose of this study is to determine if enzalutamide is an effective therapy in treating localized prostate cancer prior to prostatectomy.
- Trial name
- NCT01547299
- Testing
- Enzalutamide, Leuprolide, Dutasteride
- Where
- 4 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Pfizer
Urinary Incontinence
Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)
Prostate cancer is the most common non-cutaneous malignancy in men and is the 2nd leading cause of death from cancer in men. Radical prostatectomy is one of the treatment options available for organ-confined disease.
- Trial name
- NCT01215721
- Testing
- Vesicare
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, Irvine
Urinary Incontinence
Conservative Treatment of Postprostatectomy Incontinence
The primary purpose of this study is to test the effectiveness, impact on quality of life, and durability of non-surgical therapies for incontinence persisting at least one year after surgery.
- Trial name
- NCT00212264
- Testing
- Behavioral Therapy, Pelvic Floor Electrical Stimulation, Biofeedback
- Where
- United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Metastatic Castration-resistant Prostate Cancer
A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients
This is a randomized, multi-center, double-blind, Phase III study of radium-223 plus enzalutamide or darolutamide compared to enzalutamide or darolutamide treatment plus placebo.
- Trial name
- ESCALATE (NCT04237584)
- Testing
- Enzalutamide during Lead-in Period, Lead-in Enzalutamide followed by Radium-223/Enzalutamide, Darolutamide during Lead-in Period
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- MANA RBM
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone
- Trial name
- NCT03419234
- Testing
- Abiraterone Acetate, Androgen deprivation therapy, Cabazitaxel
- Where
- 672 sites in United States, Puerto Rico
- Volunteers
- 223 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Prostate Cancer Metastatic
68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
This was an open-label, multicenter, single dose, Phase I/II study to evaluate the safety and tolerability of a single administration of 3 mega Becquerel (MBq)/kg, but not less than 150 MBq and not more than 250 MBq, of…
- Trial name
- PROfind (NCT03490032)
- Testing
- [68Ga]-PSMA-R2
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Advanced Accelerator Applications
Castration-resistant Prostate Cancer
Oral Calcitriol With Ketoconazole in CRPC
The aim of this study is to estimate the PSA response rate with the use of ketoconazole (400mg QD + hydrocortisone 20mg AM, 10 mg PM) among men with CRPC in whom disease has progressed despite abiraterone
- Trial name
- NCT03261336
- Testing
- Calcitriol, Ketoconazole, Hydrocortisone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Donald Trump, MD
Prostatic Neoplasms, Prostate Neoplasms
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
This is a prospective, open-label, randomized, cross-over, pilot study of reprogramming therapy in patients with recurrent PCa based on rising PSA only.
- Conditions
- Prostatic Neoplasms, Prostate Neoplasms, Prostate Cancer
- Trial name
- NCT03572387
- Testing
- 5-Azacitidine, all trans retinoic acid, Lupron
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Prostate Cancer
Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients
This is an open-label, multi-centre single arm trial to investigate long-term safety and tolerability of degarelix in Korean patients with prostate cancer.
- Trial name
- NCT01215513
- Testing
- Degarelix
- Where
- 11 sites in South Korea
- Volunteers
- 127 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study
The goal of this study is to investigate the feasibility and toxicity of using prostate-specific membrane antigen-positron emission tomography (PSMA-PET) and multi-parametric magnetic resonance imagining (mpMRI) with PET-MR…
- Trial name
- NCT04176497
- Testing
- 68Ga-HBED-CC-PSMA
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer
A Trial of Degarelix in Patients With Prostate Cancer
A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer.
- Trial name
- NCT00946920
- Testing
- Degarelix, Goserelin acetate
- Where
- 126 sites in United States, Belgium and 12 more
- Volunteers
- 859 people
- Sponsor
- Ferring Pharmaceuticals
Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
This is an open label randomized phase II study for prostate cancer patients who have disease progression after hormonal therapy.
- Conditions
- Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer, Prostate Cancer
- Trial name
- NCT01313559
- Testing
- Pasireotide, Everolimus, Laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Prostate Cancer
18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer
The main purpose of this phase II trial study is to determine whether a positron emission tomography (PET)/computed tomography (CT) scan using 18F-DCFPyL affects the clinical management plan in Veterans.
- Trial name
- PROSPYL (NCT04390880)
- Testing
- 18F-DCFPyL
- Where
- United States
- Volunteers
- 239 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Prostate Cancer
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical…
- Trial name
- CAP (NCT00132301)
- Testing
- Docetaxel, Prednisone
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 298 people
- Sponsor
- VA Office of Research and Development
High Risk Prostate Cancer
Neoadjuvant BKM120 in High-risk Prostate Cancer
This is a phase II, study of BKM120 in patients with high-risk, localized prostate cancer. Eligible patients will be enrolled and scheduled to have an ultrasound-guided biopsy of the prostate to confirm high-risk disease and…
- Trial name
- NCT01695473
- Testing
- BKM120
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Won Kim
Prostate Cancer, Multiple Myeloma
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering…
- Conditions
- Prostate Cancer, Multiple Myeloma, Smoldering Multiple Myeloma (SMM), Monoclonal Gammopathy of Undetermined Significance
- Trial name
- NCT04731844
- Testing
- Curcumin plus Piperine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Rochester
Prostate Cancer
Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer
The goal of this clinical research study is to find out how treatment with abiraterone acetate in combination with prednisone and a Luteinizing Hormone-Releasing Hormone (LHRH) analogue changes the tumor in comparison to…
- Trial name
- NCT01088529
- Testing
- Abiraterone Acetate, Prednisone, LHRHa
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Cougar Biotechnology, Inc.